Axa PPP extends cancer cover to rejected NHS drug

As COVER reported yesterday, the National Institute for Health and Clinical Excellence (Nice) announced in its draft guidance that abiraterone would not be made available for standard NHS use. It cited the estimated cost of at least £63,200 per quality-adjusted life year (QALY) as being too much for the NHS to bear despite it prolonging patients lives by around three months. The decision prompted the amendments from Axa PPP which said it would now join Bupa and WPA in including coverage for the drug. A report in the Guardian said the private medical insurance (PMI) provider had cha...